Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) Short Interest Down 12.2% in October

Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) was the target of a significant decline in short interest in October. As of October 15th, there was short interest totalling 3,600 shares, a decline of 12.2% from the September 30th total of 4,100 shares. Currently, 0.1% of the company’s shares are sold short. Based on an average daily trading volume, of 23,600 shares, the days-to-cover ratio is currently 0.2 days.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Kiora Pharmaceuticals stock. Stonepine Capital Management LLC bought a new stake in Kiora Pharmaceuticals, Inc. (NASDAQ:KPRX) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 200,000 shares of the company’s stock, valued at approximately $840,000. Kiora Pharmaceuticals accounts for 0.8% of Stonepine Capital Management LLC’s investment portfolio, making the stock its 16th largest holding. Stonepine Capital Management LLC owned about 6.86% of Kiora Pharmaceuticals at the end of the most recent quarter. 76.97% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $10.00 price objective on shares of Kiora Pharmaceuticals in a research note on Thursday, August 22nd.

Kiora Pharmaceuticals Trading Down 2.2 %

Shares of NASDAQ KPRX traded down $0.08 during trading on Thursday, reaching $3.62. The stock had a trading volume of 11,876 shares, compared to its average volume of 76,325. The business’s 50-day moving average price is $3.55 and its 200-day moving average price is $4.36. Kiora Pharmaceuticals has a fifty-two week low of $3.00 and a fifty-two week high of $8.98.

Kiora Pharmaceuticals (NASDAQ:KPRX) last released its earnings results on Friday, August 9th. The company reported ($0.53) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.95) by $0.42. The company had revenue of $0.02 million during the quarter. On average, equities analysts forecast that Kiora Pharmaceuticals will post 1.17 earnings per share for the current year.

About Kiora Pharmaceuticals

Kiora Pharmaceuticals, Inc, a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases.